Glaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Buy GSK Shares
Add GSK to Watchlist
Add GSK to Alert

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1,766.50

Bid: 1,766.00

Ask: 1,766.50

Change: 36.50 (2.11%)

Spread: 0.50 (0.028%)

Open: 1,735.50

High: 1,766.50

Low: 1,735.00

Prev. Close: 1,730.00

Last checked at -

Director/PDMR Shareholding

18 Oct 2023 15:30

RNS Number : 5641Q

GSK PLC

18 October 2023

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	474
			£15.1980	709
			£15.1980	1,178

d)	Aggregated information
d)	Aggregated volume Price	2,361 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2023 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$37.0100	248
			$37.0100	391


d)	Aggregated information
d)	Aggregated volume Price	639 $37.0100
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	68
			£15.1980	111
			£15.1980	214

d)	Aggregated information
d)	Aggregated volume Price	393 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	82
			£15.1980	137
			£15.1980	208

d)	Aggregated information
d)	Aggregated volume Price	427 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	41
			£15.1980	64
			£15.1980	129

d)	Aggregated information
d)	Aggregated volume Price	234 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	128
			£15.1980	233
			£15.1980	502

d)	Aggregated information
d)	Aggregated volume Price	863 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2023 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$37.0100	23
			$37.0100	103

d)	Aggregated information
	Aggregated volume Price	126 $37.0100
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	101
			£15.1980	154
			£15.1980	290

d)	Aggregated information
d)	Aggregated volume Price	545 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	76
			£15.1980	140
			£15.1980	233

d)	Aggregated information
d)	Aggregated volume Price	449 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Phil Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	59
			£15.1980	97
			£15.1980	152

d)	Aggregated information
d)	Aggregated volume Price	308 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	121
			£15.1980	102
			£15.1980	371

d)	Aggregated information
d)	Aggregated volume Price	594 £15.1980
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£15.1980	176

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-10-16
f)	Place of the transaction	London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')

Name

Emma Walmsley

Position/status

Chief Executive Officer

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GSK plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period

Price(s) and volume(s)

Price(s)	Volume(s)
£15.1980	5020.201

Aggregated information

Aggregated volume Price

N/A (single transaction)

Date of the transaction

2023-10-16

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFEFEAEDSEDS

Date		Source	Headline
9th Sep 2020	3:11 pm	RNS	Director/PDMR Shareholding
9th Sep 2020	12:47 pm	RNS	Director/PDMR Shareholding
3rd Sep 2020	7:00 am	RNS	Sanofi/GSK: Phase 1/2 trial of COVID-19 vaccine
1st Sep 2020	3:23 pm	RNS	Total Voting Rights
13th Aug 2020	10:48 am	RNS	Director/PDMR Shareholding
6th Aug 2020	7:00 am	RNS	US FDA approves GSK’s BLENREP for multiple myeloma
3rd Aug 2020	11:31 am	RNS	Total Voting Rights
3rd Aug 2020	7:00 am	RNS	Sanofi/GSK to supply EU with 300m COVID 19 doses
31st Jul 2020	12:00 pm	RNS	Sanofi & GSK picked for Op. Warp Speed by US Gov.
29th Jul 2020	2:02 pm	RNS	Director/PDMR Shareholding
29th Jul 2020	12:00 pm	RNS	2nd Quarter Results
29th Jul 2020	7:00 am	RNS	Sanofi and GSK agree UK doses of COVID-19 vaccine
28th Jul 2020	3:23 pm	RNS	Director/PDMR Shareholding
24th Jul 2020	1:16 pm	RNS	GSK receives positive CHMP opinion for Belamaf
20th Jul 2020	7:00 am	RNS	GSK and CureVac enter collaboration
15th Jul 2020	9:31 am	RNS	Director/PDMR Shareholding
15th Jul 2020	7:00 am	RNS	FDA Panel Votes IN FAVOR of Belantamab mafodotin
14th Jul 2020	1:19 pm	RNS	Director/PDMR Shareholding
13th Jul 2020	5:42 pm	RNS	Director/PDMR Shareholding
10th Jul 2020	4:41 pm	RNS	Director/PDMR Shareholding
10th Jul 2020	3:15 pm	RNS	Director/PDMR Shareholding
10th Jul 2020	3:07 pm	RNS	Director/PDMR Shareholding
1st Jul 2020	12:25 pm	RNS	Total Voting Rights
29th Jun 2020	8:00 am	RNS	GSK’s daprodustat gains first regulatory approval
19th Jun 2020	3:22 pm	RNS	FDA Advisory Committee review belantamab mafodotin
18th Jun 2020	12:25 pm	RNS	Director/PDMR Shareholding
16th Jun 2020	12:51 pm	RNS	Director/PDMR Shareholding
11th Jun 2020	3:56 pm	RNS	Director/PDMR Shareholding
9th Jun 2020	2:16 pm	RNS	Director/PDMR Shareholding
1st Jun 2020	12:14 pm	RNS	Total Voting Rights
29th May 2020	4:41 pm	RNS	Second Price Monitoring Extn
29th May 2020	4:37 pm	RNS	Price Monitoring Extension
26th May 2020	11:53 am	RNS	Block listing Interim Review
19th May 2020	5:51 pm	RNS	Holding(s) in Company
18th May 2020	7:09 am	RNS	ViiV PrEP jab shows high efficacy over daily pill
13th May 2020	5:04 pm	RNS	Director/PDMR Shareholding
11th May 2020	6:07 pm	RNS	Director/PDMR Shareholding
7th May 2020	5:43 pm	RNS	Publication of Final Terms
7th May 2020	3:52 pm	RNS	Director/PDMR Shareholding
7th May 2020	7:56 am	RNS	GSK sells its holding in Hindustan Unilever
6th May 2020	5:40 pm	RNS	Result of AGM
4th May 2020	6:00 pm	RNS	Director/PDMR Shareholding
4th May 2020	5:40 pm	RNS	Publication of a Prospectus
4th May 2020	4:18 pm	RNS	Rights attached to ordinary shares
1st May 2020	3:45 pm	RNS	Total Voting Rights
30th Apr 2020	7:00 am	RNS	GSK’s Zejula approved in first-line ovarian cancer
29th Apr 2020	12:00 pm	RNS	1st Quarter Results
29th Apr 2020	11:00 am	RNS	Arrangements for Shareholder Webcast
16th Apr 2020	3:25 pm	RNS	Director/PDMR Shareholding
16th Apr 2020	2:21 pm	RNS	Director/PDMR Shareholding

Latest Share Chat

Glaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

Login to your account

Quickpicks are a member only feature

Login to your account